IONS vs. UTHR, NBIX, INCY, BMRN, EXAS, RGEN, EXEL, HALO, MDGL, and ALKS
Should you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Exelixis (EXEL), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), and Alkermes (ALKS). These companies are all part of the "biotechnology" industry.
Ionis Pharmaceuticals vs.
United Therapeutics (NASDAQ:UTHR) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, community ranking, valuation, media sentiment, analyst recommendations, dividends and earnings.
In the previous week, United Therapeutics had 11 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 17 mentions for United Therapeutics and 6 mentions for Ionis Pharmaceuticals. United Therapeutics' average media sentiment score of 1.53 beat Ionis Pharmaceuticals' score of 0.30 indicating that United Therapeutics is being referred to more favorably in the media.
United Therapeutics has a net margin of 40.31% compared to Ionis Pharmaceuticals' net margin of -44.58%. United Therapeutics' return on equity of 19.22% beat Ionis Pharmaceuticals' return on equity.
United Therapeutics presently has a consensus price target of $378.36, indicating a potential upside of 7.74%. Ionis Pharmaceuticals has a consensus price target of $60.65, indicating a potential upside of 90.12%. Given Ionis Pharmaceuticals' higher probable upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than United Therapeutics.
United Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500.
94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 11.9% of United Therapeutics shares are owned by insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
United Therapeutics has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
Ionis Pharmaceuticals received 101 more outperform votes than United Therapeutics when rated by MarketBeat users. However, 62.50% of users gave United Therapeutics an outperform vote while only 60.31% of users gave Ionis Pharmaceuticals an outperform vote.
Summary
United Therapeutics beats Ionis Pharmaceuticals on 14 of the 17 factors compared between the two stocks.
Get Ionis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ionis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:IONS) was last updated on 2/1/2025 by MarketBeat.com Staff
Free IONS Stock Alerts